<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhao Q</submitter><funding>NCI NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | National Institutes of Health</funding><pagination>735</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9911733</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Although tissue-resident memory T (T&lt;sub>RM&lt;/sub>) cells specific for previously encountered pathogens have been characterized, the induction and recruitment of brain T&lt;sub>RM&lt;/sub> cells following immune therapy has not been observed in the context of glioblastoma. Here, we show that T cells expressing fibrinogen-like 2 (FGL2)-specific single-chain variable fragments (T-αFGL2) can induce tumor-specific CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells that prevent glioblastoma recurrence. These CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells display a highly expanded T cell receptor repertoire distinct from that found in peripheral tissue. When adoptively transferred to the brains of either immunocompetent or T cell-deficient naïve mice, these CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells reject glioma cells. Mechanistic</pubmed_abstract><journal>Nature communications</journal><pubmed_title>FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.</pubmed_title><pmcid>PMC9911733</pmcid><funding_grant_id>R01 CA200574</funding_grant_id><pubmed_authors>Xia X</pubmed_authors><pubmed_authors>Kong L</pubmed_authors><pubmed_authors>Yan J</pubmed_authors><pubmed_authors>Heimberger AB</pubmed_authors><pubmed_authors>Fowlkes NW</pubmed_authors><pubmed_authors>Jiang S</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Hu J</pubmed_authors><pubmed_authors>Yi SF</pubmed_authors><pubmed_authors>Zhao Q</pubmed_authors><pubmed_authors>Tian X</pubmed_authors><pubmed_authors>Dao LH</pubmed_authors><pubmed_authors>Hashizume R</pubmed_authors><pubmed_authors>Jia Z</pubmed_authors><pubmed_authors>Masopust D</pubmed_authors></additional><is_claimable>false</is_claimable><name>FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.</name><description>Although tissue-resident memory T (T&lt;sub>RM&lt;/sub>) cells specific for previously encountered pathogens have been characterized, the induction and recruitment of brain T&lt;sub>RM&lt;/sub> cells following immune therapy has not been observed in the context of glioblastoma. Here, we show that T cells expressing fibrinogen-like 2 (FGL2)-specific single-chain variable fragments (T-αFGL2) can induce tumor-specific CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells that prevent glioblastoma recurrence. These CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells display a highly expanded T cell receptor repertoire distinct from that found in peripheral tissue. When adoptively transferred to the brains of either immunocompetent or T cell-deficient naïve mice, these CD8&lt;sup>+&lt;/sup> T&lt;sub>RM&lt;/sub> cells reject glioma cells. Mechanistic</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-06-01T04:00:55.371Z</modification><creation>2025-06-01T04:00:55.371Z</creation></dates><accession>S-EPMC9911733</accession><cross_references><pubmed>36759517</pubmed><doi>10.1038/s41467-023-36430-2</doi></cross_references></HashMap>